NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Multiple Technology Appraisal (MTA)

Botulinum toxin type A for treating upper and lower limb spasticity associated with stroke [ID768]

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Manufacturers/sponsors	General
Allergan (botulinum toxin type A	Allied Health Professionals Federation
[Botox])	Board of Community Health Councils
Ipsen (botulinum toxin type A	in Wales
[Dysport])	British National Formulary
Merz Pharma (botulinum toxin type Negmin)	Care Quality Commission
A [Xeomin])	Department of Health, Social Services Department of Health, Social Services
Patient/carer groups	and Public Safety for Northern Ireland
Action on Pain	Medicines and Healthcare products Pagulatory Agency
Action of Fam Afiya Trust	Regulatory AgencyNational Association of Primary Care
Arthritis and Musculoskeletal	National Association of Primary CareNational Pharmacy Association
Alliance	NHS Alliance
Black Health Agency	NHS Commercial Medicines Unit
Brain and Spine Foundation	NHS Confederation
Different strokes	Scottish Medicines Consortium
Disability Rights UK	Gooding Modified Control and
Equalities National Council	Possible comparator manufacturers
Headway - the brain injury	Actavis (baclofen, diazepam,
association	tizanidine)
 Leonard Cheshire Disability 	Arrow Generics (baclofen, diazepam)
Muslim Council of Britain	 Dr Reddy's Laboratories (diazepam,
Muslim Health Network	tizanidine)
Neurological Alliance	Mylan UK (baclofen, diazepam,
Pain Concern	tizanidine)
Pain Relief Foundation	Norgine (dantrolene sodium)
• Pain UK	Novartis (baclofen)
South Asian Health Foundation	Ranbaxy (diazepam, tizanidine)
Specialised Healthcare Alliance Strates Associations	Rosemont Pharmaceuticals (diagraps)
Stroke Association	(diazepam)
Professional groups	Sandoz (baclofen, diazepam)Wockhardt UK (diazepam)
Association of British Neurologists	vvockilatut ort (ulazepaili)
British Association and College of	Relevant research groups
Occupational Therapists	Chronic Pain Policy Coalition
	Sinomor anir only Countries

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of botulinum toxin type A for treating upper and lower limb spasticity associated with stroke [ID768]

Issue date: July 2014 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
 British Association of Stroke Physicians British Geriatrics Society British Neuropathological Society British Pain Society British Society of Rehabilitation Medicine Chartered Society of Physiotherapy Institute of Neurology National Pharmacy Association Physiotherapy Pain Association Primary Care Neurology Society Royal College of General Practitioners Royal College of Nursing Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Health Forum 	 Cochrane Movement Disorders Group Cochrane Stroke Group Health Research Authority MRC Clinical Trials Unit National Institute for Health Research Wellcome Trust Assessment Group Assessment Group TBC National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Clinical Guideline Centre Associated Public Health Groups Public Health England Public Health Wales
 Others Department of Health NHS England NHS Knowsley CCG NHS Milton Keynes CCG Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence
Provisional matrix for the proposed technology appraisal of botulinum toxin type A for treating upper and lower limb spasticity associated with stroke [ID768]
Issue date: July 2014
Page 2 of 3

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.